|
Hematological Factors and MRI in Covid-19 Infected may Predict the Prevalence of Multiple Sclerosis in the Post-Covid era
|
Bakhtiar Ebrahimirad1    , Mahnaz Taherianfard2 , Arash Mosarezaii3 |
1- PhD candidate, Dept of physiology, school of veterinary medicine- Shiraz University, Shiraz- Iran & PhD candidate, Dept of physiology, school of veterinary medicine- Shiraz University, Shiraz- Iran
2- Professor, Dept of physiology, school of veterinary medicine- Shiraz University, Shiraz- Iran & Professor, Dept of physiology, school of veterinary medicine- Shiraz University, Shiraz- Iran , taherian@shirazu.ac.ir
3- Associate Professor, Neurology department of Urmia Medical University, Urmia- Iran & Associate Professor, Neurology department of Urmia Medical University, Urmia- Iran |
|
|
Abstract: (1423 Views) |
Background and Aim: This study aimed to compare blood factors and MRI in MS+ participants (with a history of MS) and MS-(without a history of MS) to determine the prevalence of MS in MS- and increase the severity of the disease in MS+.
Materials and Methods In this cross-sectional observational study, 80 human samples were selected from 20-50-year-olds infected with COVID-19 based on PCR tests at the time of infection from February 11th, 2020 to November 20th, 2021. The research method was explained to the participants and all of them filled out and signed the informed consent form CBC, ESR, ANA, and CRP were measured in the participants' blood samples. Then, an MRI scan was done on all participants to diagnose MS.
Results: In age groups 31-40 and 41-50, ANA was significantly higher in MS+ than MS- participants. ANA was meaningfully higher in inpatient and outpatient MS+ than in inpatient and outpatient MS-. In MS+ men, CRP was higher than in MS- men. The MRI scan showed that MS plaques were observed in 13 patients with no history of MS before contracting COVID-19.
Conclusion: The results showed that CRP and ANA were higher than healthy in all participants 2.5 years after the infection of COVID-19, but this increase was greater in hospitalized and MS+ participants. Also, the MRI showed MS plaques after contracting Covid-19. |
|
| Keywords: Covid-19, Multiple sclerosis, C-reactive protein, Antinuclear Antibodies, Erythrocyte Sedimentation Rate |
|
|
Full-Text [PDF 664 kb]
(227 Downloads)
|
Type of Study: Original Research |
Subject:
Physiology and neurosciences
Received: 2023/08/2 | Accepted: 2023/11/4 | Published: 2024/10/29
|
|
|
|
|
|
|
| References |
1. 1.Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788. [ DOI:10.1371/journal.pone.0249788] [ PMID] [ ] 2. Alnajashi H, Jabbad R. Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. PLoS One. 2020;15(10):e0241103. [ DOI:10.1371/journal.pone.0241103] [ PMID] [ ] 3. Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275-301. [ DOI:10.1042/EBC20160017] [ PMID] [ ] 4. Jungen MJ, Ter Meulen BC, van Osch T, Weinstein HC, Ostelo R. Inflammatory biomarkers in patients with sciatica: a systematic review. BMC Musculoskelet Disord. 2019;20(1):156. [ DOI:10.1186/s12891-019-2541-0] [ PMID] [ ] 5. Yalachkov Y, Anschuetz V, Jakob J, Schaller-Paule MA, Schaefer JH, Reilaender A, et al. C-Reactive Protein Levels and Gadolinium-Enhancing Lesions Are Associated With the Degree of Depressive Symptoms in Newly Diagnosed Multiple Sclerosis. Front Neurol. 2021;12:719088. [ DOI:10.3389/fneur.2021.719088] [ PMID] [ ] 6. Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021;11(1):464. [ DOI:10.1038/s41598-020-79431-7] [ PMID] [ ] 7. Fahmi RM, Ramadan BM, Salah H, Elsaid AF, Shehta N. Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2021;51. [ DOI:10.1016/j.msard.2021.102921] [ PMID] 8. Toori KU, Qureshi MA, Chaudhry A, Safdar MF. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. Pak J Med Sci 2021;37(5):1435-9. [ DOI:10.12669/pjms.37.5.4194] [ PMID] [ ] 9. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014;194:145-58. [ DOI:10.1016/j.virusres.2014.09.011] [ PMID] [ ] 10. Taherifard E, Taherifard E. Neurological complications of COVID-19: a systematic review. Neurol Res. 2020;42(11):905-12. [ DOI:10.1080/01616412.2020.1796405] [ PMID] 11. Neema M, Stankiewicz J, Arora A, Guss ZD, Bakshi R. MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics. 2007;4(4):602-17. [ DOI:10.1016/j.nurt.2007.08.001] [ PMID] [ ] 12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. [ DOI:10.1002/ana.22366] [ PMID] [ ] 13. Naghavi S, Kavosh A, Adibi I, Shaygannejad V, Arabi S, Rahimi M, et al. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. Mult Scler Relat Disord. 2022;57:103335. [ DOI:10.1016/j.msard.2021.103335] [ PMID] [ ] 14. Lima M, Aloizou AM, Siokas V, Bakirtzis C, Liampas I, Tsouris Z, et al. Coronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia? Rev Neurosci. 2022;33(7):703-20. [ DOI:10.1515/revneuro-2021-0148] [ PMID] 15. Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol. 2020;27(9):1764-73. [ DOI:10.1111/ene.14277] [ PMID] [ ] 16. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206-9. [ DOI:10.1021/acschemneuro.0c00201] [ PMID] 17. Alter TH, Helbig T, Chiappetta G. Case report: Multiple sclerosis diagnosis after anterior lumbar interbody fusion and presumed COVID-19 infection. Surg Neurol Int. 2022;13:125. [ DOI:10.25259/SNI_192_2022] [ PMID] [ ] 18. Jeon YH, Choi S, Park JH, Lee JK, Yeo NS, Lee S, et al. Sudden Death Associated With Possible Flare-Ups of Multiple Sclerosis After COVID-19 Vaccination and Infection: A Case Report and Literature Review. J Korean Med Sci. 2023;38(10):e78. [ DOI:10.3346/jkms.2023.38.e78] [ PMID] [ ] 19. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol. 2007;79:357-75. [ DOI:10.1016/S0074-7742(07)79016-5] [ PMID] 20. Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13:128. [ DOI:10.1186/1471-2377-13-128] [ PMID] [ ] 21. Libbey JE, Fujinami RS. Viral mouse models used to study multiple sclerosis: past and present. Arch Virol. 2021;166(4):1015-33. [ DOI:10.1007/s00705-021-04968-5] [ PMID] [ ] 22. Peker BO, Sener AG, Kaptan Aydogmus F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J Immunol Methods. 2021;499:113174. [ DOI:10.1016/j.jim.2021.113174] [ PMID] [ ] 23. Taeschler P, Cervia C, Zurbuchen Y, Hasler S, Pou C, Tan Zea. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy. 2022;77(8):2415-30. [ DOI:10.1111/all.15302] [ PMID] [ ] 24. Mejdoub S, Feki S, Farhat N, Dammak M, Hachicha H, Sakka S, et al. Antinuclear antibodies positivity is not rare during multiple sclerosis and is associated with relapsing status and IgG oligoclonal bands positivity. Rev Neurol (Paris). 2022;178(8):812-6. [ DOI:10.1016/j.neurol.2021.11.016] [ PMID] 25. Alnajashi H, Alshamrani F. Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2021;5:2021. [ DOI:10.1186/s41983-021-00284-6] 26. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-4. [ DOI:10.1016/j.medmal.2020.03.007] [ PMID] [ ] 27. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420-9. [ DOI:10.1093/ije/dyab012] [ PMID] [ ] 28. Moosazadeh M, Nabinezhad-Male F, Afshari M, Nasehi MM, Shabani M, Kheradmand M, et al. Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis. AIMS Neurosci. 2021;8(2):239-53. [ DOI:10.3934/Neuroscience.2021013] [ PMID] [ ] 29. Ismailova A, White JH. Vitamin D, infections and immunity. Rev Endocr Metab Disord. 2022;23(2):265-77. [ DOI:10.1007/s11154-021-09679-5] [ PMID] [ ] 30. Nurshad A. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409-11. [ DOI:10.1002/jmv.26097] [ PMID] [ ] 31. Ji AL, Liu ZH, Chen WW, Huang WJ. The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period. Eur Rev Med Pharmacol Sci. 2016;20(20):4274-6. 32. Nazeri M, Bazrafshan H, Abolhasani Foroughi A. Serum inflammatory markers in patients with multiple sclerosis and their association with clinical manifestations and MRI findings. Acta Neurol Belg. 2022;122(5):1187-93. [ DOI:10.1007/s13760-021-01647-9] [ PMID] 33. M.M. E, Al-Kaisy M, Regeia WAL, Khan HJ. The Prognostic Accuracy of Neutrophil -Lymphocyte Ratio in COVID-19 Patients. Front Emerg Med. 2021;5(1):e8. 34. Wu L, Zou S, Wang C, Tan X, Yu M. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in Chinese Han population from Chaoshan region in South China. BMC Cardiovasc Disord. 2019;19(1):125.
https://doi.org/10.1186/s12872-022-02563-3 [ DOI:10.1186/s12872-019-1110-7] 35. Huang WC, Lin HC, Yang YH, Hsu CW, Chen NC, Tsai WC, et al. Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;58:103514. [ DOI:10.1016/j.msard.2022.103514] [ PMID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Ethics code: IR.US.REC.1401.033
Ebrahimirad B, Taherianfard M, Mosarezaii A. Hematological Factors and MRI in Covid-19 Infected may Predict the Prevalence of Multiple Sclerosis in the Post-Covid era. SJKU 2024; 29 (4) :82-94 URL: http://sjku.muk.ac.ir/article-1-8025-en.html
|
